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Diagnostic of Andropause: a Problem not yet Solved
Andropause, also known as late-onset hypogonadism (LOH) or hypogo-nadism in aging males, is due to alterations in the testicular and hypotha-
lamic-pituitary functions (1). A reduction in both the hormone production 
by the Leydig cells and in the GnRH secretion by the hypothalamus takes 
place, leading to inadequate secretion of LH by the pituitary (1). Some el-
ders, however, have normal LH levels in the presence of hypogonadism and 
its increase is not required for the LOH diagnosis (2). The androgen defi -
ciency in elderly males is normally partial and only a few of them clearly dis-
play hormonal levels under the lower limit for young and healthy males, 
which makes the hypogonadism diagnosis harder in such cases (1). 
In this issue of ABE&M, two articles from Clapauch e cols. (3,4) evalua-
te the diagnosis of hypogonadism associated to the age in two group of men, 
with or without osteoporosis. In one of the articles, the total testosterone 
(TT), calculated free testosterone (cFT), and calculated bioavailable testoste-
rone (cBT) dosages were evaluated (3) and in the other article the relation of 
those testosterone dosages with three acknowledged questionnaires of the 
gonadal function evaluation were also analyzed (4).
The decrease of free and total serum testosterone levels is gradual and pro-
gresses with age. The total testosterone level remains constant up to the age of 50 
to 55 and after that, a progressive decrease takes place (5,6), as confi rmed by 
Clapauch e cols. (3). Free testosterone and albumin-bound testosterone, which 
represents the bioavailable testosterone, progressively decrease at the ages of 25 
to 75 years, due to the continuous increase of SHBG with age (5,6) 
However, the hypogonadism diagnosis by evaluation of testosterone do-
sages in blood is not reliable because the procedure may present technical 
laboratorial diffi culties. In the same city there may be clinical laboratories 
using different methods and normal ranges for testosterone analysis, and that 
makes each lab responsible to improve its own reference values by themselves 
(2). In addition to that, weekly variations in the testosterone dosage may oc-
cur in elderly men whose testosterone levels vary around the lower limits 
(1,2), leading to the necessity of at least two dosages in different days, in or-
der to determine hypogonadism with a reliable laboratorial parameter which 
was also demonstrated by Clapauch e cols. (3). 
The signs and symptoms of androgen defi ciency are not specifi c and they 
can change with age, associated diseases, severity and duration of the andro-
gen defi ciency, variation of the androgenic sensitivity and previous testostero-
ne therapy (1). Moreover, the testosterone level threshold under which 
adverse effects and the onset of androgenic defi ciency symptoms are associa-
ted is not known (1). For instance, Clapauch e cols. (4) found that total sco-
res equal to or higher than 27 in the Aging Male’s Symptoms Scale (AMS) 
questionnaire were only related to TT levels below 400 ng/dL and no asso-
ciation was found in cBT or cFT. 
































Clapauch e cols. (4) also evaluated the advantage of 
three questionnaires as the screening tool for LOH 
diagnosis: Androgen Defi ciency of the Aging Male, 
AMS, and International Index of Erectile Function 
(IIEF-5) (for references, please see 4). However, no 
important correlation between the total testosterone 
(TT), calculated free testosterone (cFT) and calculated 
bioavailable testosterone (cBT) with three questionnai-
res was found. 
Testosterone is a pro-hormone which originates 
two other hormones that are active in the male me-
tabolism: estradiol (E2) and 5-alpha-dihydrotestoste-
rone (DHT) (7,8). It is thus not surprising that no 
form of testosterone evaluation was related to the 
questionnaires evaluated by Clapauch e cols. (4), ac-
cordingly to all other studies mentioned in the arti-
cle, which also evaluated circulating testosterone 
forms, but not its active metabolites (4). Free and 
bioavailable E2 levels can decline due to the increase 
of SHBG (7) and this may jeopardize its benefi cial 
effect on bone, brain, lipids, and cardiovascular sys-
tem (7). Nevertheless, a correlation between the E2 
level and AMS scale was not observed (9). Testoste-
rone is converted by 5-alpha-reductases into DHT 
which has an important action in sexual activity, se-
xual characters and brain (8). The use of transdermal 
DHT signifi cantly improved sexual function evalua-
ted by IIEF-5 (8), a typical action of the DHT not 
correlated with the testosterone levels of the study 
presented by Clapauch e cols. (4). 
The syndrome related to the male aging process, 
evaluated by the questionnaires, could also be due to 
factors other than the testosterone level decrease, such 
as the age-related defi cit of GH and IGF-1, central and 
peripheral nervous system alterations, inactivity and 
immobility (1, 2). On the other hand, the age-related 
declination of testosterone levels is almost not seen in 
healthy males, which are those who do not have any 
chronic disease or who have a healthy lifestyle (5) and a 
signifi cant number of males remain eugonadic even at 
advanced ages (6). 
In conclusion, the use of questionnaires used in the 
study made by Clapauch e cols. (4) for andropause 
diagnosis is not recommended (1); the diagnosis for 
androgen defi ciency should only be made in males with 
consistent testosterone-defi ciency-related symptoms 
and signs and with an unequivocal decrease of testoste-
rone levels (1,2); in addition, hormonal dosage as the 
screening tool for androgen defi ciency is not recom-
mended in the general population (1).
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